Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 55 articles:
HTML format

Single Articles

    July 2021
  1. PENG M, He J, Xue Y, Yang X, et al
    The role of hypertension on the severity of COVID-19: a review.
    J Cardiovasc Pharmacol. 2021 Jul 22. pii: 00005344-900000000-98170.
    PubMed     Abstract available

  2. KRYSIAK R, Basiak M, Okopien B
    Impact of lisinopril on cardiometabolic risk factors in men with hypertension and early-onset androgenetic alopecia: a pilot study.
    J Cardiovasc Pharmacol. 2021 Jul 20. pii: 00005344-900000000-98169.
    PubMed     Abstract available

  3. WANG Y, Wang JW, Wang Y, Yang B, et al
    Monitoring Antihypertensive Medication Adherence by LC-MS/MS: Method Establishment and Clinical Application.
    J Cardiovasc Pharmacol. 2021 Jul 9. pii: 00005344-900000000-98173.
    PubMed     Abstract available

    June 2021
  4. HAMMOUD S, Kurdi M, van den Bemt BJ
    Impact of Fasting on Cardiovascular Outcomes in Patients with Hypertension.
    J Cardiovasc Pharmacol. 2021 Jun 29. pii: 00005344-900000000-98181.
    PubMed     Abstract available

    May 2021
  5. YANG S, Zhang H, Yang P, Wang C, et al
    Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021;77:650-659.
    PubMed     Abstract available

    April 2021
  6. MCCOY EK, Lisenby KM
    Aprocitentan (a dual endothelin receptor antagonist) for Treatment-Resistant Hypertension.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98239.
    PubMed     Abstract available

  7. YAMAGATA K, Yamori Y
    Altered properties of neurons and astrocytes and the effects of food components in stroke-prone spontaneously hypertensive rats.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98237.
    PubMed     Abstract available

  8. GILEWSKI W, Banach J, Rogowicz D, Wolowiec L, et al
    Treatment of hypertension due to immunosuppressive therapy after solid organ transplantation - pharmacological approach.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98236.
    PubMed     Abstract available

    March 2021
  9. RAJABI S, Najafipour H, Farsangi SJ, Joukar S, et al
    Quercetin, Perillyl alcohol and Berberine ameliorate right ventricular disorders in experimental pulmonary arterial hypertension: Effects on miR-204, miR-27a, fibrotic, apoptotic and inflammatory factors.
    J Cardiovasc Pharmacol. 2021 Mar 12. pii: 00005344-900000000-98234.
    PubMed     Abstract available

    February 2021
  10. VILHENA JC, Lopes de Melo Cunha L, Jorge TM, de Lucena Machado M, et al
    Acai reverses adverse cardiovascular remodeling in renovascular hypertension: a comparative effect with Enalapril.
    J Cardiovasc Pharmacol. 2021 Feb 19. pii: 00005344-900000000-98275.
    PubMed     Abstract available

  11. GAO HL, Yu XJ, Liu KL, Zuo YY, et al
    Chronic Infusion of Astaxanthin Into Hypothalamic Paraventricular Nucleus Modulates Cytokines and Attenuates the Renin-Angiotensin System in Spontaneously Hypertensive Rats.
    J Cardiovasc Pharmacol. 2021;77:170-181.
    PubMed     Abstract available

    November 2020
  12. RIGOPOULOS AG, Kalogeropoulos AS, Tsoporis JN, Sakadakis EA, et al
    Heat shock protein 70 is associated with cardioversion outcome and recurrence of symptomatic recent onset atrial fibrillation in hypertensive patients.
    J Cardiovasc Pharmacol. 2020 Nov 24. doi: 10.1097/FJC.0000000000000962.
    PubMed     Abstract available

  13. MAQSOOD MH, Rubab K, Anwar F, Afzal Khan MT, et al
    A Systematic Review of Randomized Controlled Trials Comparing Renal Sympathetic Denervation versus Sham Procedure for the Management of Uncontrolled Hypertension.
    J Cardiovasc Pharmacol. 2020 Nov 20. doi: 10.1097/FJC.0000000000000961.
    PubMed     Abstract available

  14. LU J, Tian Y, Gu J, Qiu M, et al
    Comparative study of metabolite changes after antihypertensive therapy with calcium channel blockers or angiotensin type 1 receptor blockers.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000958.
    PubMed     Abstract available

    October 2020
  15. REGINA SM, Maria L, Reinhold F, Elisabeth S, et al
    Rapid Switch from Subcutaneous to Intravenous Treprostinil in Precapillary Pulmonary Hypertension by Pump Implantation.
    J Cardiovasc Pharmacol. 2020 Oct 15. doi: 10.1097/FJC.0000000000000933.
    PubMed     Abstract available

  16. DE JESUS SILVA F, Drummond FR, Fidelis MR, Freitas MO, et al
    Continuous aerobic exercise prevents detrimental remodeling and right heart myocyte contraction and calcium cycling dysfunction in pulmonary artery hypertension.
    J Cardiovasc Pharmacol. 2020 Oct 9. doi: 10.1097/FJC.0000000000000928.
    PubMed     Abstract available

    September 2020
  17. SOUZA-PAULA E, Polonio LCC, Zochio GP, Pinho da Silva K, et al
    Anticontractile effect of perivascular adipose tissue but not of endothelium is enhanced by hydrogen sulfide stimulation in hypertensive pregnant rat aortae.
    J Cardiovasc Pharmacol. 2020 Sep 18. doi: 10.1097/FJC.0000000000000917.
    PubMed     Abstract available

    June 2020
  18. TANG M, Wang R, Feng P, Dong Q, et al
    Dihydroartemisinin Attenuates Pulmonary Hypertension via Inhibition of Pulmonary Vascular Remodeling in Rats.
    J Cardiovasc Pharmacol. 2020 Jun 5. doi: 10.1097/FJC.0000000000000862.
    PubMed     Abstract available

    May 2020
  19. GRZESK G, Karasek D, Kusiak M
    Thrombocytopenia During Prostacyclin Analogue Therapies of Pulmonary Arterial Hypertension-Possible Pathomechanisms and Implications.
    J Cardiovasc Pharmacol. 2020;75:421-425.
    PubMed     Abstract available

    April 2020
  20. HOPPER RK, Ivy DD, Yung D, Mullen MP, et al
    Pharmacokinetics of Oral Treprostinil in Children with Pulmonary Arterial Hypertension.
    J Cardiovasc Pharmacol. 2020 Apr 16. doi: 10.1097/FJC.0000000000000842.
    PubMed     Abstract available

    March 2020
  21. LV Q, Wang Y, Li Y, Zhao L, et al
    Rosuvastatin reverses hypertension-induced changes in the aorta structure and endothelium-dependent relaxation in rats through suppression of apoptosis and inflammation.
    J Cardiovasc Pharmacol. 2020 Mar 19. doi: 10.1097/FJC.0000000000000828.
    PubMed     Abstract available

  22. YAO NA, Niazi ZR, Najmanova I, Kamagate M, et al
    Preventive beneficial effect of an aqueous extract of Phyllanthus amarus Schum. & Thonn. (Euphorbiaceae) on DOCA-salt-induced hypertension, cardiac hypertrophy and dysfunction, and endothelial dysfunction in rats.
    J Cardiovasc Pharmacol. 2020 Mar 12. doi: 10.1097/FJC.0000000000000825.
    PubMed     Abstract available

  23. DONG F, Zhang J, Chen X, Zhang S, et al
    Chrysin Alleviates Monocrotaline-induced Pulmonary Hypertension (MCTPH) in Rats via Regulation of Intracellular Calcium Homeostasis in pulmonary arterial smooth muscle cells (PASMCs).
    J Cardiovasc Pharmacol. 2020 Mar 9. doi: 10.1097/FJC.0000000000000823.
    PubMed     Abstract available

  24. GAVOTTO A, Thomas F, Werner O, Moreau J, et al
    Use of treprostinil in pediatric pulmonary hypertension: case reports and review of the literature.
    J Cardiovasc Pharmacol. 2020 Mar 9. doi: 10.1097/FJC.0000000000000820.
    PubMed     Abstract available

    February 2020
  25. GRZESK G, Karasek D, Kusiak M
    Thrombocytopenia during prostacyclin analogue therapies of pulmonary arterial hypertension - possible pathomechanisms and implications.
    J Cardiovasc Pharmacol. 2020 Feb 5. doi: 10.1097/FJC.0000000000000806.
    PubMed     Abstract available

    January 2020
  26. PARIKH KS, Doerfler S, Shelburne N, Kennedy K, et al
    Experience in Transitioning from Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    J Cardiovasc Pharmacol. 2020 Jan 13. doi: 10.1097/FJC.0000000000000800.
    PubMed     Abstract available

    December 2019
  27. HUANG Y, Wu X, Wu M, Chu J, et al
    Antihypertensive and Vasodilatory Effects of Qingda Granules by Suppression of Calcium Influx and the AKT Pathway.
    J Cardiovasc Pharmacol. 2019;74:549-557.
    PubMed     Abstract available

  28. LAHERA V
    Mechanisms Underlying the Antihypertensive and Vasodilatory Effects of Qingda Granules.
    J Cardiovasc Pharmacol. 2019;74:511-512.

    November 2019
  29. DONG F, Zhang J, Zhu S, Lan T, et al
    Chrysin Alleviates Chronic Hypoxia-Induced Pulmonary Hypertension by Reducing Intracellular Calcium Concentration in Pulmonary Arterial Smooth Muscle Cells.
    J Cardiovasc Pharmacol. 2019;74:426-435.
    PubMed     Abstract available

    October 2019
  30. CHIH LING W, Rais Mustafa M, Devi Murugan D
    Therapeutic implications of nitrite in hypertension.
    J Cardiovasc Pharmacol. 2019 Oct 18. doi: 10.1097/FJC.0000000000000771.
    PubMed     Abstract available

    DOCA/Salt: much more than a model of hypertension.
    J Cardiovasc Pharmacol. 2019 Oct 9. doi: 10.1097/FJC.0000000000000753.
    PubMed     Abstract available

    August 2019
  32. BAL NB, Han S, Usanmaz SE, Kiremitci S, et al
    Activation of Liver X Receptors by GW3965 Attenuated Deoxycorticosterone Acetate-Salt Hypertension-Induced Cardiac Functional and Structural Changes.
    J Cardiovasc Pharmacol. 2019;74:105-117.
    PubMed     Abstract available

    July 2019
  33. DA SILVA JS, Sun X, Ahmad S, Wang H, et al
    GPER agonist G1 improves diastolic function and attenuates cardiac RAS activation in estrogen-deficient hypertensive rats.
    J Cardiovasc Pharmacol. 2019 Jul 25. doi: 10.1097/FJC.0000000000000721.
    PubMed     Abstract available

  34. BAL NB, Han S, Usanmaz SE, Kiremitci S, et al
    Activation of Liver X Receptors by GW3965 attenuated DOCA-salt hypertension-induced cardiac functional and structural changes.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000693.
    PubMed     Abstract available

  35. HUANG Y, Wu X, Wu M, Chu J, et al
    Anti-hypertensive and Vasodilatory Effects of Qingda Granules by Suppression of Calcium Influx and the AKT Pathway.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000686.
    PubMed     Abstract available

  36. ZHANG S, Zhang Y, Ahsan MZ, Yuan Y, et al
    Atorvastatin Attenuates Cold-induced Hypertension by Preventing Gut Barrier Injury.
    J Cardiovasc Pharmacol. 2019 Jul 11. doi: 10.1097/FJC.0000000000000690.
    PubMed     Abstract available

    June 2019
  37. KANUKULA R, Esam H, Sundstrom J, Rodgers A, et al
    Does Co-administration of Antihypertensive Drugs and Statins Alter Their Efficacy and Safety? A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2019;73:352-358.
    PubMed     Abstract available

    March 2019
  38. SALAH E, Bastacky SI, Jackson EK, Tofovic SP, et al
    2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury.
    J Cardiovasc Pharmacol. 2019;73:165-177.
    PubMed     Abstract available

    February 2019
  39. HAMANO G, Yamamoto K, Takami Y, Takeshita H, et al
    Effects of low-dose sacubitril/valsartan on different stages of cardiac hypertrophy in salt-loaded hypertensive rats.
    J Cardiovasc Pharmacol. 2019 Feb 28. doi: 10.1097/FJC.0000000000000662.
    PubMed     Abstract available

    November 2018
  40. SIMA M, Slanar O
    Letter to the editor regarding "Therapeutic drug monitoring to assess drug adherence in assumed resistant hypertension: a comparison with directly observed therapy in three non-adherent patients".
    J Cardiovasc Pharmacol. 2018 Nov 30. doi: 10.1097/FJC.0000000000000637.
    PubMed     Abstract available

  41. ZHANG H, Mo X, Zhou Z, Zhu Z, et al
    Detection of putative functional SNPs in blood pressure loci and validation of association between SNP in WBP1L and hypertension in the Chinese Han population.
    J Cardiovasc Pharmacol. 2018 Nov 5. doi: 10.1097/FJC.0000000000000633.
    PubMed     Abstract available

  42. BAMAIYI AJ, Norton GR, Peterson V, Norman G, et al
    Limited Impact of beta-Adrenergic Receptor Activation on Left Ventricular Diastolic Function in Rat Models of Hypertensive Heart Disease.
    J Cardiovasc Pharmacol. 2018;72:242-251.
    PubMed     Abstract available

    October 2018
  43. LEZAMA-MARTINEZ D, Flores-Monroy J, Fonseca-Coronado S, Hernandez-Campos M, et al
    Combined Antihypertensive Therapies that Increase Expression of Cardioprotective Biomarkers Associated with the Renin-Angiotensin and Kallikrein-Kinin Systems.
    J Cardiovasc Pharmacol. 2018 Oct 29. doi: 10.1097/FJC.0000000000000629.
    PubMed     Abstract available

    June 2018
  44. MOKOTEDI L, Michel FS, Woodiwiss AJ, Norton GR, et al
    Effects of High Salt-Low Potassium Diet on Blood Pressure and Vascular Reactivity in Male Sprague Dawley Rats.
    J Cardiovasc Pharmacol. 2018;71:340-346.
    PubMed     Abstract available

    May 2018
  45. FEYZ L, Bahmany S, Daemen J, van den Meiracker AH, et al
    Therapeutic drug monitoring to assess drug adherence in assumed resistant hypertension: a comparison with directly observed therapy in three non-adherent patients.
    J Cardiovasc Pharmacol. 2018 May 23. doi: 10.1097/FJC.0000000000000602.
    PubMed     Abstract available

    February 2018
  46. ABID S, Kebe K, Houssaini A, Tomberli F, et al
    New NO Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease.
    J Cardiovasc Pharmacol. 2018 Feb 8. doi: 10.1097/FJC.0000000000000570.
    PubMed     Abstract available

    January 2018
  47. EKHOLM M, Jekell A, Wallen NH, Gigante B, et al
    The effects of angiotensin converting enzyme inhibition and alpha 1-adrenergic receptor blockade on inflammation and hemostasis in human hypertension.
    J Cardiovasc Pharmacol. 2018 Jan 30. doi: 10.1097/FJC.0000000000000565.
    PubMed     Abstract available

  48. PARK Y, Choi BG, Rha SW, Baek MJ, et al
    Selective ss1-Blockers Are Not Associated With New-onset Diabetes Mellitus in Hypertensive Patients.
    J Cardiovasc Pharmacol. 2018;71:38-45.
    PubMed     Abstract available

    November 2017
  49. REPAS SJ, Saad NS, Janssen PML, Elnakish MT, et al
    Memantine, an NMDA Receptor Antagonist, Prevents Thyroxin-induced Hypertension, but Not Cardiac Remodeling.
    J Cardiovasc Pharmacol. 2017;70:305-313.
    PubMed     Abstract available

    October 2017
    Antihypertensive therapy and new on-set of diabetes mellitus: The double edge sword.
    J Cardiovasc Pharmacol. 2017 Oct 31. doi: 10.1097/FJC.0000000000000553.

    June 2017
  51. HANSEN MS, Andersen A, Holmboe S, Schultz JG, et al
    Levosimendan prevents and reverts right ventricular failure in experimental pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2017 Jun 19. doi: 10.1097/FJC.0000000000000508.
    PubMed     Abstract available

    May 2017
  52. MAGUBANE M, Michel FS, Erlwanger KH, Norton GR, et al
    Prevention of betaeta-Adrenergic-Induced Adverse Cardiac Remodelling by Gonadectomy in Male but not Female Spontaneously Hypertensive Rats.
    J Cardiovasc Pharmacol. 2017 May 30. doi: 10.1097/FJC.0000000000000506.
    PubMed     Abstract available

  53. JAIN M, Bhosale V, Tripathi D, Singh H, et al
    Antihypertensive drugs aliskiren, nebivolol, and olmesartan reduce hypertension by reducing endothelial microparticle and regulating angiogenesis.
    J Cardiovasc Pharmacol. 2017 May 9. doi: 10.1097/FJC.0000000000000503.
    PubMed     Abstract available

    March 2017
  54. IZZO JL JR, Zappe DH, Jia Y, Hafeez K, et al
    Efficacy and safety of crystalline valsartan/sacubitril (LCZ696) compared to placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study.
    J Cardiovasc Pharmacol. 2017 Mar 23. doi: 10.1097/FJC.0000000000000485.
    PubMed     Abstract available

    April 2016
  55. KAMIMURA D, Uchino K, Ishigami T, Hall ME, et al
    Activation of Peroxisome Proliferator-Activated Receptor gamma Prevents Development of Heart Failure with Preserved Ejection Fraction; Inhibition of Wnt-beta-catenin Signaling as a Possible Mechanism.
    J Cardiovasc Pharmacol. 2016.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.